Status:

ACTIVE_NOT_RECRUITING

Standardized Instruments to Provide Diagnostic and Prognostic Information in Mild Traumatic Brain Injury (mTBI)

Lead Sponsor:

Carey Balaban

Collaborating Sponsors:

Uniformed Services University of the Health Sciences

University of Miami

Conditions:

Mild Traumatic Brain Injury

Eligibility:

All Genders

18-50 years

Phase:

NA

Brief Summary

This study will establish the capability of a suite of conventional tests and the Neurolign Dx\_100 I-PAS goggle system to reliably and objectively detect mTBI in an acute setting when comparing indiv...

Detailed Description

The investigators will employ a comprehensive assessment battery to include vestibular/oculomotor, cognitive, and symptom domains using measures that are consistent with the NIH/NINDS common data elem...

Eligibility Criteria

Inclusion

  • For the mTBI group, participants must present to a recruitment site within 10 days of injury with a diagnosed concussion that meets all of the following criteria:
  • clear mechanism of injury (i.e., direct or indirect impact to head),
  • Glasgow Coma Scale= 13-15, 3) observed or reported signs (e.g., loss of consciousness, amnesia, or confusion) or symptoms (e.g., headache, dizziness, nausea), and
  • neurosensory symptoms.
  • For Control group, participants will have minor, non-surgical injuries (e.g., sprains, strains) not requiring hospital admission and no history of mTBI will be recruited from the same study sites.

Exclusion

  • History of moderate to severe TBI characterized by any of the following:
  • Penetrating head trauma
  • GCS\< 13 at the time of injury
  • Associated with LOC \> 30 minutes or amnesia \>24 hours
  • Associated with subdural or epidural hemorrhage
  • mTBI history
  • mTBI Group - history of mTBI within the last 6 months or experiencing head injury symptoms immediately prior to the current head injury or history of 3 or more mTBIs
  • Controls - No history of mTBI within the last 12 months and no presence of any mTBI-related symptoms at time of enrollment
  • Presence of severe aphasia
  • History of diagnosed psychiatric disorder (e.g., schizophrenia)
  • Documented neurological disorders (e.g., Epilepsy, stroke, dementia)
  • Pregnancy (females will be asked if they are pregnant)
  • Prior disorders of hearing and balance including:
  • Meniere's disease
  • Multiple sclerosis
  • Vestibular neuritis
  • Vestibular schwannoma
  • Sudden sensorineural hearing loss
  • History of tumor of the brain or central nervous system

Key Trial Info

Start Date :

September 30 2020

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

November 30 2025

Estimated Enrollment :

450 Patients enrolled

Trial Details

Trial ID

NCT04372797

Start Date

September 30 2020

End Date

November 30 2025

Last Update

January 6 2025

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Naval Medical Center San Diego

San Diego, California, United States, 92134

2

University of Miami

Miami, Florida, United States, 33136

3

University of Pittsburgh

Pittsburgh, Pennsylvania, United States, 15203